News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,059 Results
Type
Article (47506)
Company Profile (715)
Press Release (680826)
Multimedia
Podcasts (133)
Webinars (26)
Section
Business (206105)
Career Advice (2380)
Deals (37232)
Drug Delivery (141)
Drug Development (81907)
Employer Resources (176)
FDA (16633)
Job Trends (15397)
News (349441)
Policy (31793)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2185)
Academic (1)
Accelerated approval (42)
Adcomms (27)
Allergies (165)
Alliances (50258)
ALS (199)
Alzheimer's disease (1773)
Antibody-drug conjugate (ADC) (396)
Approvals (16896)
Artificial intelligence (646)
Autoimmune disease (242)
Automation (48)
Bankruptcy (380)
Best Places to Work (11425)
BIOSECURE Act (23)
Biosimilars (203)
Biotechnology (442)
Bladder cancer (181)
Brain cancer (69)
Breast cancer (683)
Cancer (5387)
Cardiovascular disease (464)
Career advice (2000)
Career pathing (43)
CAR-T (310)
CDC (39)
Celiac Disease (1)
Cell therapy (856)
Cervical cancer (39)
Clinical research (70587)
Collaboration (2022)
Company closure (6)
Compensation (1274)
Complete response letters (89)
COVID-19 (2663)
CRISPR (109)
C-suite (1040)
Cystic fibrosis (156)
Data (7092)
Decentralized trials (3)
Denatured (24)
Depression (165)
Dermatology (56)
Diabetes (541)
Diagnostics (7089)
Digital health (50)
Diversity (7)
Diversity, equity & inclusion (41)
Drug discovery (311)
Drug pricing (209)
Drug shortages (30)
Duchenne muscular dystrophy (286)
Earnings (89674)
Editorial (68)
Employer branding (24)
Employer resources (156)
Events (120747)
Executive appointments (1084)
FDA (20081)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1667)
Gene editing (237)
Generative AI (60)
Gene therapy (750)
GLP-1 (1092)
Government (3883)
Grass and pollen (8)
Guidances (393)
Healthcare (17867)
HIV (75)
Huntington's disease (57)
IgA nephropathy (94)
Immunology and inflammation (300)
Immuno-oncology (89)
Indications (158)
Infectious disease (2986)
Inflammatory bowel disease (210)
Inflation Reduction Act (14)
Influenza (130)
Intellectual property (279)
Interviews (465)
IPO (17515)
IRA (52)
Job creations (4357)
Job search strategy (1633)
JPM (68)
Kidney cancer (18)
Labor market (91)
Layoffs (646)
Leadership (42)
Legal (8018)
Liver cancer (100)
Longevity (26)
Lung cancer (717)
Lymphoma (398)
Machine learning (51)
Management (62)
Manufacturing (969)
MASH (186)
Medical device (14348)
Medtech (14429)
Mergers & acquisitions (20892)
Metabolic disorders (1464)
mRNA (197)
Multiple sclerosis (175)
NASH (22)
Neurodegenerative disease (413)
Neuropsychiatric disorders (111)
Neuroscience (3235)
Neurotech (1)
NextGen: Class of 2026 (6422)
Non-profit (3328)
Now hiring (74)
Obesity (709)
Opinion (338)
Ovarian cancer (180)
Pain (237)
Pancreatic cancer (262)
Parkinson's disease (349)
Partnered (36)
Patents (573)
Patient recruitment (615)
Peanut (63)
People (61136)
Pharmaceutical (128)
Pharmacy benefit managers (34)
Phase 1 (22201)
Phase 2 (31287)
Phase 3 (23291)
Pipeline (7200)
Policy (309)
Postmarket research (2197)
Preclinical (9277)
Press Release (71)
Prostate cancer (277)
Psychedelics (59)
Radiopharmaceuticals (321)
Rare diseases (1090)
Real estate (6125)
Recruiting (75)
Regulatory (24890)
Reports (46)
Research institute (2221)
Resumes & cover letters (379)
Rett syndrome (33)
RNA editing (20)
RSV (87)
Schizophrenia (173)
Series A (288)
Series B (212)
Service/supplier (26)
Sickle cell disease (114)
Special edition (28)
Spinal muscular atrophy (180)
Sponsored (44)
Startups (4015)
State (2)
Stomach cancer (20)
Supply chain (120)
Tariffs (97)
The Weekly (107)
Vaccines (1094)
Venture capital (108)
Weight loss (471)
Women's health (99)
Worklife (22)
Date
Today (165)
Last 7 days (721)
Last 30 days (2837)
Last 365 days (31233)
2026 (8239)
2025 (31427)
2024 (36648)
2023 (41423)
2022 (52412)
2021 (56525)
2020 (53875)
2019 (45301)
2018 (34498)
2017 (34007)
2016 (32933)
2015 (38618)
2014 (31343)
2013 (29962)
2012 (27925)
2011 (28019)
2010 (25778)
Location
Africa (804)
Alabama (96)
Alaska (7)
Arizona (282)
Arkansas (12)
Asia (45864)
Australia (7491)
California (12519)
Canada (3534)
China (1309)
Colorado (522)
Connecticut (543)
Delaware (371)
Europe (99350)
Florida (1829)
Georgia (392)
Hawaii (4)
Idaho (62)
Illinois (919)
India (86)
Indiana (582)
Iowa (24)
Japan (498)
Kansas (130)
Kentucky (47)
Louisiana (37)
Maine (80)
Maryland (1440)
Massachusetts (9191)
Michigan (362)
Minnesota (696)
Mississippi (7)
Missouri (148)
Montana (35)
Nebraska (27)
Nevada (136)
New Hampshire (86)
New Jersey (3381)
New Mexico (31)
New York (3280)
North Carolina (1678)
North Dakota (9)
Northern California (6167)
Ohio (368)
Oklahoma (20)
Oregon (49)
Pennsylvania (2509)
Puerto Rico (27)
Rhode Island (52)
South America (1184)
South Carolina (76)
South Dakota (1)
Southern California (4839)
Tennessee (180)
Texas (1984)
United States (44429)
Utah (366)
Vermont (1)
Virginia (302)
Washington D.C. (83)
Washington State (1023)
West Virginia (4)
Wisconsin (129)
Wyoming (2)
729,059 Results for "gene company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics’ liver-directed gene editor.
February 26, 2026
·
1 min read
·
Tristan Manalac
Gene therapy
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on local delivery and the small amount of drug required to overcome key safety concerns.
March 23, 2026
·
7 min read
·
Tristan Manalac
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
·
3 min read
·
Nick Paul Taylor
Press Releases
Faron Pharmaceuticals Ltd: Holding(s) in Company - March 12, 2026
March 13, 2026
·
3 min read
Rare disease
Why Industry Is Questioning FDA’s Data-Sharing Push in Cell and Gene Therapy
After the FDA’s first-ever public listening meeting on data-sharing in the cell and gene therapy space, new draft guidance aims to standardize the practice. But recent decisions call into question whether shared evidence and prior knowledge will accelerate development in rare diseases.
March 12, 2026
·
5 min read
·
Ana Mulero
Sickle cell disease
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
February 23, 2026
·
6 min read
·
Heather McKenzie
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Complete response letters
REGENXBIO’s Hunter Syndrome Gene Therapy Fails To Win FDA Nod
The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission for the gene therapy RGX-121.
February 10, 2026
·
2 min read
·
Tristan Manalac
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with
CNBC
, the agency confirmed to the biotech that a sham surgery–controlled study is needed before submitting the gene therapy for approval.
March 2, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
March 2, 2026
·
5 min read
1 of 72,906
Next
